Lebwohl M, Deodhar A, Griffiths CEM, et al. - This study attempted to evaluate the malignancy risk in patients with secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Researchers enrolled safety data from 49 clinical trials with secukinumab-treated patients: 10 685 patients with psoriasis, 2,523 with PsA and 1,311 with AS. The risk of malignancy was low for up to 5 years of secukinumab treatment in this large safety analysis. These outcomes suggest the long-term use of secukinumab in these indications.